U.S. markets closed
  • S&P 500

    3,647.53
    -7.51 (-0.21%)
     
  • Dow 30

    29,136.51
    -124.30 (-0.42%)
     
  • Nasdaq

    10,829.50
    +26.58 (+0.25%)
     
  • Russell 2000

    1,658.55
    +2.66 (+0.16%)
     
  • Crude Oil

    78.52
    +1.81 (+2.36%)
     
  • Gold

    1,635.60
    +2.20 (+0.13%)
     
  • Silver

    18.36
    -0.12 (-0.65%)
     
  • EUR/USD

    0.9593
    -0.0018 (-0.19%)
     
  • 10-Yr Bond

    3.9640
    +0.0860 (+2.22%)
     
  • GBP/USD

    1.0717
    +0.0034 (+0.32%)
     
  • USD/JPY

    144.8420
    +0.1620 (+0.11%)
     
  • BTC-USD

    19,086.92
    -101.37 (-0.53%)
     
  • CMC Crypto 200

    438.30
    -20.84 (-4.54%)
     
  • FTSE 100

    6,984.59
    -36.36 (-0.52%)
     
  • Nikkei 225

    26,571.87
    +140.32 (+0.53%)
     

Global Pulmonary Arterial Hypertension Drug Market to Surpass US$ 11,220.2 Million by 2030 - Coherent Market Insights

·4 min read

SEATTLE, Sept. 13, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global Pulmonary Arterial Hypertension drug market is estimated to be valued at US$ 7,310.1 Million in 2022 and is expected to exhibit a CAGR of 5.5% over the forecast period (2022-2030).

Coherent Market Insights Logo
Coherent Market Insights Logo


Key Trends and Analysis of the Global Pulmonary Arterial Hypertension Drug Market:

Major players are focusing on drug releases and regulatory approvals, which are expected to drive the global Pulmonary Arterial Hypertension drug market growth during the forecast period. For instance, the U.S. Food and Drug Administration (FDA) approved United Therapeutics' Trevyent New Drug Application (NDA) in September 2019. Trevyent is a drug-device combination product that includes PatchPump technology, which allows treprostilin to be administered subcutaneously.

Furthermore, key players operating in the market are focusing on adoption of inorganic growth strategies such as acquisition and collaboration, in order to expand their product portfolio and presence in the global Pulmonary Arterial Hypertension drug market. For instance, in September 2018, United Therapeutics Corporation, an American publicly traded biotechnology company and MannKind Corporation which is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products, collaborated on the development and commercialization of dry powder formulations of treprostinil. The companies also intend to sign a research agreement for MannKind to conduct research. This research must be conducted by Mannkind on behalf of United Therapeutics on products outside the scope of the license and cooperation agreement.

Request for Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/203

Key Market Takeaways:

The global Pulmonary Arterial Hypertension drug market is expected to exhibit a CAGR of 5.5% during the forecast period, owing to increasing launches and approvals of new products. Major market players are focusing on developing the product and obtaining regulatory approval, which is expected to promote market growth during the forecast period. For instance, in March 2019, the U.S. Food and Drug Administration approved the first generic drug for the treatment of pulmonary arterial hypertension (PAH), Ambrisentan (Letairis).

Among distribution channel, hospital pharmacies is estimated to account for highest market share in 2022. Increasing number of hospitalization due to patients suffering from Pulmonary Arterial Hypertension is fuelling the market growth of hospital pharmacies segment.

Among Region, North America is expected to dominate the market in the forecast period as the medical infrastructure developed in the U.S. promotes the availability of advanced therapies. In addition, increased awareness, high diagnostic rates and supportive government initiatives have controlled the growth of the regional market. Moreover, supporting legislation such as the Rare Disease Act of 2002 and the Orphan Drug Act (ODA) of 1983 in the U.S. encouraged the development of new drugs for PAH.

Key players operating in the global Pulmonary Arterial Hypertension drug market include United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/203

Detailed Segmentation:

Global Pulmonary Arterial Hypertension Drug Market, By Drug Class:

  • Endothelin Receptor Antagonists (ERAs)

  • Phosphodiesterase-5 (PDE-5) Inhibitors

  • Soluble Guanylate Cyclase (sGC) Stimulators

  • Prostacyclin Analogue

  • Calcium Channel Blockers

  • Others

Global Pulmonary Arterial Hypertension Drug Market, By Route of Administration:

  • Oral

  • Inhaled

  • Intravenous

  • Subcutaneous

Global Pulmonary Arterial Hypertension Drug Market, By Distribution Channel:

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

Global Pulmonary Arterial Hypertension Drug Market, By Region:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/203

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com 
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedInTwitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/global-pulmonary-arterial-hypertension-drug-market-to-surpass-us-11-220-2-million-by-2030--coherent-market-insights-301623552.html

SOURCE Coherent Market Insights